Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma

Visit https://www.peervoice.com/YQM860 to view the entire programme with slides. After completing “Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma”, participants will be able to: Recall safety and efficacy data evaluating the combination of an antibody-drug conjugate (ADC) plus an immune checkpoint inhibitor (ICI) for the first-line management of locally advanced/metastatic urothelial carcinoma (la/mUC); Apply recently updated guideline recommendations regarding first-line management of patients with la/mUC; and Recognise adverse events associated with the combination of an ADC and ICI for the management of la/mUC.